Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer' returned 1 results - Page 1 of 1  FEATURED RESULTS Drug Delivery in Cancer - Technologies, Markets and Companies Antibody Drug Target Atlas in Oncology Cancer Diagnostic Testing World Markets Cancer Risk Assessment: Chemical Carcinogenesis, Hazard Eval... Pharmacogenetics of Breast Cancer: Towards the Individualiza...   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Stakeholder Opinions: Bone Metastases - Impending Patent Expiries May Help Make or Break Newer Agents   Datamonitor, March 2008, Pages: 100 : Denosumab: Phase II results in bisphosphonate-naïve breast cancer patients 63 Figure 23: Alpharadin: Phase II results in hormone-refractory prostate cancer patients with bone metastases 69 Amgen Inc. ASCO Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network